Inferra AI / Company / AUPH / Slides
Aurinia Pharmaceuticals — Presentation (company IR deck)
Aurinia Pharmaceuticals (AUPH) · 16 slides · Filed Oct 29, 2026
Every slide of this earnings presentation, with the text as published. Open the original deck ↗ · All AUPH deck slides
Slide 1 — Results from a Phase 1 Study
June 30, 2025 Aritinercept (AUR20) A Dual BAF/APRIL Inhibitor for the Potential Treatment of Autoimune Diseases Results from a Phase 1 Study
Slide 2 — Forward
Forward - Loking Statements This presentation contains forward - loking information within the meaning of aplicable Canadian securities law and forward - loking statements within the meaning of aplicable U.S. securities law. We caution investors that forward - looking statements are based on manag asumptions as of the date of this presentation and involve substantial risks and uncertainties that could cause the actual outcomes to difer materialy from what we curently expect. These risks and uncertainties include, but are not limited to, those asociated with the development of aritinercept and other risks and uncertainties identified in our filings with the U.S. Securities and Exchange Comision. Forward - loking statements in this presentation aply only as of the date made, and we undertake no obligation to update or revise any forward - loking statements to reflect subsequent events or circumstances. Aditional information related to Aurinia , including a detailed list of risks and uncertainties afecting Aurinia and its busines, can be found in Aurinia‘s most recent Anual Report on Form 10 - K and its other public available filings available by acesing the Canadian Securities Administrators‘ System for Electronic Document Ana w.sedarplus.ca or the U.S. Securities and Exchange Commis and Retrieval System (EDGAR) website at w.sec.gov/edgar , and on Aurinia‘s website at w.auriniapharma.com . 2
Slide 3 — Aritinercept
Aritinercept (AUR20) Is a Dual BAF/APRIL Inhibitor • Aritinercept contains a BCMA - enginered extracelular binding domain optimized for superior afinity to BAF and APRIL (others use TACI - enginered extracelular binding domain) Þ BCMA has a stronger natural afinity for APRIL than TACI a • Aritinercept contains an IgG4 Fc domain with no apreciable efector function (others use IgG1 Fc domain) Þ IgG4 is considered the least inflamatory acros the IgG subclases, in part because it porly activates the complement system b Enginered extracelular domain of BCMA receptor AUR20 BAF APRIL Fc domain of IgG4 Aritinercept BAF=B cel - activating factor; APRIL=a proliferation - inducing ligand; BCMA=B cel maturation antigen; TACI=t ransmembrane activator and CAML interactor; Fc=fragment crystalizable region; IgG4=imunoglobulin G4 a Mathur et al., J Clin Med 2023 b Oskam et al., Front Imun 2023 3
Slide 4 — Role of BAF and APRIL
Role of BAF and APRIL • BAF and APRIL are important cytokines that regulate B cel survival and diferentiation, whose targets are expresed on B cels at diferent stages of B cel development a • Targeting both BAF and APRIL depletes a broader set of B cels, including plasma cels, than targeting a single cytokine • Aritinercept may prevent the activation of autoreactive B cels and reduce their numbers and asociated imunoglobulins (antibodies) in the body, thereby reducing important drivers of B cel - mediated autoimune diseases B Cel Maturation b APRIL Dependency BAF Dependency a Mathur et al., J Clin Med 2023 b Schrezenmeier et al., J Am Soc Nephrol 2018 4